Fiche publication
Date publication
octobre 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul
,
Pr FORNECKER Luc-Matthieu
,
Pr UBEAUD-SEQUIER Genevieve
Tous les auteurs :
Nivoix Y, Launoy A, Lutun P, Moulin JC, Phai Pang KA, Fornecker LM, Wolf M, Leveque D, Letscher-Bru V, Beretz L, Ubeaud-Sequier G, Herbrecht R
Lien Pubmed
Résumé
OBJECTIVES: The aim of our study was to assess the adherence to labelling and international guidelines for antifungal prescribing. METHODS: A retrospective study was performed in intensive care units in addition to the oncology and haematology department, which covered 70% of antifungal consumption at Hautepierre Hospital, Strasbourg, France. On reviewing medical charts, the antifungal prescription was examined in relation to the recommendations of indication, dosage, risk of drug-drug interactions and, where appropriate, antifungal susceptibility testing. Treatments were considered appropriate, inappropriate or debatable. RESULTS: Between January and April 2007, 199 treatments were given for 179 different episodes in 133 adult patients. Treatments were prescribed for pre-emptive or targeted therapy (n = 90, with 60 for candidiasis, 26 for aspergillosis and 4 for other mould diseases), empirical therapy (n = 17) and primary (n = 81) or secondary (n = 11) prophylaxis. Fluconazole accounted for 67% of prescriptions, followed by voriconazole (19%), caspofungin (10%), posaconazole (2%), conventional or liposomal amphotericin B (2%), itraconazole (
Référence
J Antimicrob Chemother. 2012 Oct;67(10):2506-13
